Neurogene Inc.
NGNE
$16.80
-$0.98-5.51%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 33.45% | 24.88% | 48.13% | 103.47% | -- |
| Gross Profit | -31.30% | -22.70% | -48.13% | -103.47% | -- |
| SG&A Expenses | 79.30% | 82.52% | 49.88% | 26.97% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.48% | 35.11% | 12.55% | -1.88% | -- |
| Operating Income | -40.76% | -33.32% | -12.55% | 1.88% | -- |
| Income Before Tax | -4.50% | 2.70% | 21.67% | 34.26% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.50% | 2.70% | 21.67% | 34.26% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.50% | 2.70% | 21.67% | 34.26% | -- |
| EBIT | -40.76% | -33.32% | -12.55% | 1.88% | -- |
| EBITDA | -43.68% | -35.71% | -13.28% | 2.17% | -- |
| EPS Basic | 148.96% | 121.00% | 63.39% | -283.81% | -- |
| Normalized Basic EPS | 82.30% | 20.39% | -103.88% | -852.77% | -- |
| EPS Diluted | 148.95% | 120.98% | 63.37% | -283.88% | -- |
| Normalized Diluted EPS | 82.30% | 20.39% | -103.88% | -852.77% | -- |
| Average Basic Shares Outstanding | 642.56% | 198.68% | 14.34% | -88.49% | -- |
| Average Diluted Shares Outstanding | 642.56% | 198.68% | 14.34% | -88.49% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
